Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : Receives $2.49 Million as R&D Tax Incentive from French Government

09/29/2021 | 08:51am EST


ę MT Newswires 2021
All news about IMMUTEP LIMITED
12/02Immutep Doses First Five Patients in Study of Triple Combination Cancer Treatment, Find..
MT
12/01IMMUTEP : Reports Good Safety from First Five Patients in Triple Combination Therapy Efti ..
PU
12/01IMMUTEP : Application for quotation of securities - IMM
PU
11/29IMMUTEP : Notification regarding unquoted securities - IMM
PU
11/25IMMUTEP : Results of Annual General Meeting
PU
11/25IMMUTEP : AGM 2021 - CEO's presentation
PU
11/25IMMUTEP : AGM 2021 - Chairman's Address
PU
11/22IMMUTEP : Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy..
PU
11/22IMMUTEP : Goetzpartners securities -Data highlights efti efficacy and potential central ro..
PU
11/19Immutep Completes Recruitment for Phase 2 Study of Therapy Candidate for Several Types ..
MT
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 1,67 M 1,18 M 1,18 M
Net income 2022 -39,3 M -27,8 M -27,8 M
Net cash 2022 82,0 M 57,9 M 57,9 M
P/E ratio 2022 -6,41x
Yield 2022 -
Capitalization 401 M 285 M 284 M
EV / Sales 2022 192x
EV / Sales 2023 18,0x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,47 AUD
Average target price 1,23 AUD
Spread / Average Target 161%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
FrÚdÚric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED13.25%285
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-40.67%24 745